Fundamentals Hub
TVRD Tvardi Therapeutics, Inc.
TVRD financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 14 annual and 0 of 54 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$207.16M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(713) 489-8654
EIN
000000000
Headquarters
SUGAR LAND, TX, 77478
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names:
Cara Therapeutics, Inc. (2013–2025)
· Cara Therapeutics Inc (2005–2010)
▼ Key Metrics (TTM)
As of Jun 30, 2026Financials
Revenue
-
Net Income
$-26.06M
Total Assets
$17.52M
Total Equity
$8.38M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-310.9%
Return on Assets
-148.8%
Current Ratio
1.87x
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| Revenue | - | $7.14M | $20.97M |
| OPERATING EXPENSES | |||
| R&D Expense | $18.01M | $23.65M | $108.51M |
| SG&A Expense | $8.74M | $4.46M | $27.78M |
| Operating Income | $-26.75M | $-28.11M | $-121.50M |
| NON-OPERATING INCOME / EXPENSE | |||
| Interest Income | $700.00K | $700.00K | - |
| Other Income/Expense | $7.16M | $-2.04M | $3.59M |
| Pretax Income | - | $-71.27M | $-118.51M |
| Income Tax | $0 | $0 | $0 |
| Net Income | $-18.21M | $-29.40M | $-118.51M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-3.26 | $-11.42 | $-26.26 |
| Diluted Shares | 7.78M | 2.57M | 4.51M |
| EBITDA | $-26.65M | $-28.01M | $-121.24M |
| Depreciation & Amortization | $95.00K | $95.00K | $259.00K |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $20.73M | $31.61M | $51.78M |
| Short-term Investments | $10.08M | - | - |
| Accounts Receivable | - | $407.00K | $2.77M |
| Inventory | - | $900.00K | $2.82M |
| Other Current Assets | $727.00K | $72.00K | $8.15M |
| Current Assets | $31.54M | $31.69M | $116.16M |
| PP&E (Net) | $52.00K | $84.00K | $3.32M |
| Intangible Assets | $322.00K | $385.00K | - |
| Other Noncurrent Assets | $17.00K | $17.00K | - |
| Noncurrent Assets | $535.00K | $3.51M | $9.69M |
| Total Assets | $32.07M | $35.20M | $125.84M |
| LIABILITIES | |||
| Accounts Payable | $3.22M | $2.19M | $11.58M |
| Other Current Liabilities | $321.00K | $8.00K | - |
| Current Liabilities | $11.04M | $10.37M | $25.59M |
| Noncurrent Liabilities | $85.00K | $30.46M | $43.17M |
| Total Liabilities | $11.13M | $40.83M | $68.76M |
| EQUITY | |||
| Common Stock | $9.00K | $2.00K | $5.00K |
| Additional Paid-in Capital | $131.38M | $1.10M | $742.09M |
| Retained Earnings | $-110.45M | $-92.24M | $-684.75M |
| Accumulated OCI | $8.00K | - | $-260.00K |
| Total Equity | $20.95M | $-91.13M | $57.09M |
| Temporary Equity | - | $85.50M | - |
| Total Liabilities & Equity | $32.07M | $35.20M | $125.84M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 9.38M | 2.57M | 4.54M |
| Check: A − (L + E + Temp. Equity) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-23.50M | $-18.31M | $-92.08M |
| Capital Expenditures | - | $1.05M | $2.38M |
| Cash from Investing | $-10.08M | $0 | $43.46M |
| Cash from Financing | $22.70M | $27.00M | $38.15M |
| Free Cash Flow | - | $-19.35M | $-94.45M |
| Beginning Cash (CFS) | $31.61M | $22.92M | $64.15M |
| Net Change in Cash | $-10.88M | $8.70M | $-10.47M |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | $20.73M | $31.61M | $53.68M |
| Cash per BS | $20.73M | $31.61M | $51.78M |
| Cash scope difference (CFS − BS) | - | - | $1.91M |
| Cash per CFS | $20.73M | $31.61M | $53.68M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is Tvardi Therapeutics, Inc. profitable?
No. Tvardi Therapeutics, Inc. reported $-26.06M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.